Wendy's has told Nelson Peltz's Trian Fund Management and its partners that a $1.4 billion offer is not enough. The $7.35-per-share cash bid, made on Oct. 28, would take the struggling burger chain private. The board's independent committee concluded the proposal "substantially undervalues" the company and ignores the gains its ongoing turnaround could produce. On this point, the board is right to say no.
The timing matters. Wendy's reported third-quarter results on the same day, and they carry a mixed message. Same-store sales declined for a seventh straight quarter, a worrying sign for any chain that is still trying to win back customers. Yet quarterly earnings and revenue beat Wall Street's expectations. A company that is beating forecasts while its core sales shrink is not a company that has run out of options. It is one that needs time and disciplined execution.
Shareholders should also weigh the history. Peltz's firm Triarc bought Wendy's in 2008 for $2.3 billion, sold Arby's, and returned Wendy's to stand-alone status. Peltz later spent 17 years on Wendy's board before being named chairman emeritus in 2024. Trian executive Peter May and Peltz's son, Bradley, still sit on the board. Familiarity with the business is not the same as a fair price for outside shareholders, and a group with this much insider history should face a hard negotiation.
The board's response has drawn criticism for its tools. Wendy's adopted a one-year shareholder rights plan, commonly called a poison pill, and said the Trian-led group rejected a standstill agreement that would have paused further share purchases. A poison pill is a blunt instrument. It protects shareholders from a lowball bid, but it also limits their ability to decide for themselves. The board should make clear that the pill is a defensive measure with a defined purpose, not a permanent wall.
The stock has lost about 60% of its value over the last three years, and the takeover offer had lifted it. Shareholders deserve a board that can prove, with specific turnaround targets, why its valuation is higher than $7.35 per share. If Wendy's can show that, the rejection will look wise. If it cannot, the next bid may be the last one on the table.